Distribution of KRAS and BRAF Mutations in Metastatic Colorectal Cancers in Turkish Patients |
Gorukmez, Orhan
(Medical Genetics Unit, Sevket Yilmaz Training and Research Hospital)
Yakut, Tahsin (Department of Medical Genetics, School of Medicine, Uludag University) Gorukmez, Ozlem (Department of Medical Genetics, School of Medicine, Uludag University) Sag, Sebnem Ozemri (Department of Medical Genetics, School of Medicine, Uludag University) Karkucak, Mutlu (Medical Genetics Unit, Sakarya Training and Research Hospital) Kanat, Ozkan (Department of Medical Oncology, School of Medicine, Uludag University) |
1 | Benedix F, Kube R, Meyer F, et al (2010). Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Diseases Colon Rectum, 53, 57-64. DOI |
2 | Brand T, Wheeler D (2012). KRAS mutant colorectal tumors: past and present. Small GTPases, 3, 34-9. DOI |
3 | Brenner H, Kloor M, Pox C (2014). Colorectal cancer. Lancet, 383, 1490-502. DOI |
4 | Bufill J (1990). Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Internal Med, 113, 779-88. DOI |
5 | Chang Y, Chang S, Yeh K, et al (2013). RAS, BRAF, and TP53 gene mutations in Taiwanese colorectal cancer patients. Onkologie, 36, 719-24. |
6 | Ciardiello F, Tortora G (2008) Drug therapy: EGFR antagonists in cancer treatment. New Engl J Med, 358, 1160-74. DOI |
7 | Cunningham D, Humblet Y, Siena S, et al (2004). Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med, 351, 337-45. DOI |
8 | Di Nicolantonio F, Martini M, Molinari F, et al (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol, 26, 5705-12. DOI |
9 | Ferreira C, Aran V, Zalcberg-Renault I, et al (2014). KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. Bmc Gastroenterol, 14. |
10 | Friday B, Adjei A (2008). Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res, 14, 342-46. DOI |
11 | Iacopetta B (2002). Are there two sides to colorectal cancer? Int J Cancer, 101, 403-8. DOI |
12 | Jean G, Shah S (2008). Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy, 28, 742-54. DOI |
13 | Pai R, Jayachandran P, Koong A, et al (2012). BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. American J Surgical Pathol, 36, 744-52. DOI |
14 | Lin J, Chang S, Wang H, et al (2006). Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J Surgical Oncol, 94, 234-41. DOI |
15 | Marchoudi N, Joutei H, Jouali F, et al (2013). Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer. Pathologie Biologie, 61, 273-6. DOI |
16 | Ozen F, Ozdemir S, Zemheri E, et al (2013). The proto-oncogene kras and braf profiles and some clinical characteristics in colorectal cancer in the turkish population. Genetic Testing Molecular Biomarkers, 17, 135-9. DOI |
17 | Patel G, Karapetis C (2013). Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manage Res, 21, 387-400. |
18 | Roberts P, Der C (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene, 26, 3291-310. DOI |
19 | Rosty C, Young J, Walsh M, et al (2013). Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathol, 26, 825-34. DOI |
20 | Samowitz W, Curtin K, Schaffer D, et al (2000). Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev, 9, 1193-7. |
21 | Shen Y, Wang J, Han X, et al (2013). Effectors of epidermal growth factor receptor pathway: the genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. Plos One, 8. |
22 | Venook A (2005), Epidermal growth factor receptor-targeted treatment for advanced colorectal carcinoma. Cancer, 103, 2435-46. DOI |
23 | Soong R, Powell B, Elsaleh H, et al (2000). Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma: influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer, 36, 2053-60. DOI |
24 | Sugai T, Habano W, Jiao Y, et al (2006). Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis - Proposal for new molecular profile of colorectal carcinomas. J Molecular Diagnostics, 8, 193-201. DOI |
25 | Tong J, Lung R, Sin F, et al (2014). Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. Cancer Biology Therapy, 15, 768-76. DOI |
26 | Yokota T (2012). Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers? Anti-Cancer Agents in Medicinal Chemistry, 12, 163-71. DOI |
27 | Yokota T, Ura T, Shibata N, et al (2011). BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. British J Cancer, 104, 856-62. DOI |
28 | Zlobec I, Bihl M, Schwarb H, et al (2010). Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer, 127, 367-80. |